REPL heads into its June 4 earnings with one of the most combustible positioning setups in small-cap biotech: a heavily shorted stock that has tripled in a month.
The short-side squeeze pressure is genuine. Short interest has climbed 43% over the past month to reach 33.4% of the free float — more than one in three shares sold short. Yet the stock closed at $9.00 on Monday, up 83% on the week and 260% higher than a month ago. That's the arithmetic of a short squeeze in motion: sellers added to positions into a collapsing price, then the price reversed violently. Despite the short-side pain, borrow conditions remain surprisingly relaxed — availability runs at 228%, well above the 52-week trough of 41.6%, meaning there is no meaningful lending-pool pressure compounding the squeeze. Cost to borrow holds at just 0.53%, confirming the shorts are not being forced out by funding stress. The short score, though easing slightly from a peak of 68 earlier in May, still registers 64.6 — elevated, and consistent with a stock where bearish conviction runs deep even after a brutal month.
Options traders, however, are not rushing to hedge into the number. The put/call ratio moved up to 0.29 on Monday — above its 20-day mean of 0.20 but well below the 52-week high of 0.98 — and has spent the past several weeks trending at some of the lowest readings of the past year. The z-score of 0.93 is barely above neutral. That relative calm in the options market is a notable contrast: shorts are heavy, but options players are not paying up for downside protection ahead of the report.
The analyst picture underwent a dramatic reset on April 13, when a cluster of downgrades — JP Morgan to Underweight, Leerink to Market Perform with a target cut from $11 to $2, Jefferies to Hold from Buy, Wedbush to Neutral — landed simultaneously. The trigger was disappointing RP1 efficacy data and FDA questions about the Phase 3 trial design. That wall of downgrades crystallised the bear case: response rates that trail competing therapies, limited cash reserves, and a trial architecture the regulator has questioned. The lone recent counterpoint came June 1, when Wedbush — one of the firms that downgraded in April — raised its target from $2 to $6 while keeping a Neutral rating, a modest acknowledgment that the stock's collapse may have overshot. The consensus mean target of $4.67 sits well below the current $9.00 price, meaning the Street as a whole has not caught up with the rally. Bulls point to the RPx platform's mechanistic logic and RP1's continued potential in hard-to-treat solid tumors; bears have not moved off their April position.
Institutional ownership adds another layer of complexity. Ridgeback Capital Management entered as a new holder with 6.25 million shares as of May 14 — a fresh position filed just weeks into the stock's recovery. Suvretta Capital Management similarly appears as a near-full new position of 4.2 million shares. These are meaningful reads: specialist healthcare funds moving in while sell-side analysts have not yet upgraded. The CEO, CFO, CMO, and Executive Chairman all sold shares on May 18 at $5.08 — a price now well below market — trades that in hindsight look like routine disposals at what turned out to be a temporary level, though they were filed while short interest was still building.
Thursday's print is less about Replimune's quarterly financials and more about whether management can address the FDA's trial design concerns and outline a credible cash runway — the two pillars that collapsed the stock in April and whose resolution the new institutional buyers appear to be betting on.
See the live data behind this article on ORTEX.
Open REPL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
